American Association for Cancer Research

sorry, we can't preview this file

23266066cir180595-sup-207908_3_supp_5489168_pysx7j.pptx (4.46 MB)

Supplemental Figures 1-8 from The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Download (4.46 MB)
posted on 2023-04-04, 01:03 authored by Sangeetha Palakurthi, Mari Kuraguchi, Sima J. Zacharek, Enrique Zudaire, Wei Huang, Dennis M. Bonal, Jeffrey Liu, Abha Dhaneshwar, Kristin DePeaux, Martha R. Gowaski, Dyane Bailey, Samuel N. Regan, Elena Ivanova, Catherine Ferrante, Jessie M. English, Aditya Khosla, Andrew H. Beck, Julie A. Rytlewski, Catherine Sanders, Sylvie Laquerre, Mark A. Bittinger, Paul T. Kirschmeier, Kathryn Packman, Pasi A. Janne, Christopher Moy, Kwok-Kin Wong, Raluca I. Verona, Matthew V. Lorenzi

Supplemental Figures 1-8



The success of targeted or immune therapies is often hampered by the emergence of resistance and/or clinical benefit in only a subset of patients. We hypothesized that combining targeted therapy with immune modulation would show enhanced antitumor responses. Here, we explored the combination potential of erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor under clinical development, with PD-1 blockade in an autochthonous FGFR2K660N/p53mut lung cancer mouse model. Erdafitinib monotherapy treatment resulted in substantial tumor control but no significant survival benefit. Although anti–PD-1 alone was ineffective, the erdafitinib and anti–PD-1 combination induced significant tumor regression and improved survival. For both erdafitinib monotherapy and combination treatments, tumor control was accompanied by tumor-intrinsic, FGFR pathway inhibition, increased T-cell infiltration, decreased regulatory T cells, and downregulation of PD-L1 expression on tumor cells. These effects were not observed in a KRASG12C-mutant genetically engineered mouse model, which is insensitive to FGFR inhibition, indicating that the immune changes mediated by erdafitinib may be initiated as a consequence of tumor cell killing. A decreased fraction of tumor-associated macrophages also occurred but only in combination-treated tumors. Treatment with erdafitinib decreased T-cell receptor (TCR) clonality, reflecting a broadening of the TCR repertoire induced by tumor cell death, whereas combination with anti–PD-1 led to increased TCR clonality, suggesting a more focused antitumor T-cell response. Our results showed that the combination of erdafitinib and anti–PD-1 drives expansion of T-cell clones and immunologic changes in the tumor microenvironment to support enhanced antitumor immunity and survival.

Usage metrics

    Cancer Immunology Research